Ibogaine

Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures

Deborah C Mash, Craig A. Kovera, John Pablo, Rachel F. Tyndale, Frank D. Ervin, Izben C. Williams, Edward G. Singleton, Manny Mayor

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term drug abstinence from addictive substances, including psychostimulants and opiates. Anecdotal reports attest that a single dose of ibogaine eliminates opiate withdrawal symptoms and reduces drug craving for extended periods of time. The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. The majority of ibogaine biotransformation proceeds via CYP2D6, including the O-demethylation of ibogaine to 12-hydroxyibogamine (noribogaine). Blood concentration-time effect profiles of ibogaine and noribogaine obtained for individual subjects after single oral dose administrations demonstrate complex pharmacokinetic profiles. Ibogaine has shown preliminary efficacy for opiate detoxification and for short-term stabilization of drug-dependent persons as they prepare to enter substance abuse treatment. We report here that ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification. Self-reports of depressive symptoms were also significantly lower after ibogaine treatment and at 30 days after program discharge. Because ibogaine is cleared rapidly from the blood, the beneficial aftereffects of the drug on craving and depressed mood may be related to the effects of noribogaine on the central nervous system.

Original languageEnglish
Pages (from-to)394-401
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume914
StatePublished - Dec 4 2000

Fingerprint

Ibogaine
Pharmacokinetics
Safety
Opiate Alkaloids
Detoxification
Pharmaceutical Preparations
Substance-Related Disorders
Drugs
Efficacy
Tabernaemontana
Blood
Apocynaceae
Dose
Indole Alkaloids
Thirst
Ceremonial Behavior
Cytochrome P-450 CYP2D6
Substance Withdrawal Syndrome
Western Africa
Hunger

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mash, D. C., Kovera, C. A., Pablo, J., Tyndale, R. F., Ervin, F. D., Williams, I. C., ... Mayor, M. (2000). Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 914, 394-401.

Ibogaine : Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. / Mash, Deborah C; Kovera, Craig A.; Pablo, John; Tyndale, Rachel F.; Ervin, Frank D.; Williams, Izben C.; Singleton, Edward G.; Mayor, Manny.

In: Annals of the New York Academy of Sciences, Vol. 914, 04.12.2000, p. 394-401.

Research output: Contribution to journalArticle

Mash, DC, Kovera, CA, Pablo, J, Tyndale, RF, Ervin, FD, Williams, IC, Singleton, EG & Mayor, M 2000, 'Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures', Annals of the New York Academy of Sciences, vol. 914, pp. 394-401.
Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC et al. Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences. 2000 Dec 4;914:394-401.
Mash, Deborah C ; Kovera, Craig A. ; Pablo, John ; Tyndale, Rachel F. ; Ervin, Frank D. ; Williams, Izben C. ; Singleton, Edward G. ; Mayor, Manny. / Ibogaine : Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. In: Annals of the New York Academy of Sciences. 2000 ; Vol. 914. pp. 394-401.
@article{608e9ab8484344b89047fc0cd4645e34,
title = "Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures",
abstract = "Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term drug abstinence from addictive substances, including psychostimulants and opiates. Anecdotal reports attest that a single dose of ibogaine eliminates opiate withdrawal symptoms and reduces drug craving for extended periods of time. The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. The majority of ibogaine biotransformation proceeds via CYP2D6, including the O-demethylation of ibogaine to 12-hydroxyibogamine (noribogaine). Blood concentration-time effect profiles of ibogaine and noribogaine obtained for individual subjects after single oral dose administrations demonstrate complex pharmacokinetic profiles. Ibogaine has shown preliminary efficacy for opiate detoxification and for short-term stabilization of drug-dependent persons as they prepare to enter substance abuse treatment. We report here that ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification. Self-reports of depressive symptoms were also significantly lower after ibogaine treatment and at 30 days after program discharge. Because ibogaine is cleared rapidly from the blood, the beneficial aftereffects of the drug on craving and depressed mood may be related to the effects of noribogaine on the central nervous system.",
author = "Mash, {Deborah C} and Kovera, {Craig A.} and John Pablo and Tyndale, {Rachel F.} and Ervin, {Frank D.} and Williams, {Izben C.} and Singleton, {Edward G.} and Manny Mayor",
year = "2000",
month = "12",
day = "4",
language = "English",
volume = "914",
pages = "394--401",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Ibogaine

T2 - Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures

AU - Mash, Deborah C

AU - Kovera, Craig A.

AU - Pablo, John

AU - Tyndale, Rachel F.

AU - Ervin, Frank D.

AU - Williams, Izben C.

AU - Singleton, Edward G.

AU - Mayor, Manny

PY - 2000/12/4

Y1 - 2000/12/4

N2 - Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term drug abstinence from addictive substances, including psychostimulants and opiates. Anecdotal reports attest that a single dose of ibogaine eliminates opiate withdrawal symptoms and reduces drug craving for extended periods of time. The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. The majority of ibogaine biotransformation proceeds via CYP2D6, including the O-demethylation of ibogaine to 12-hydroxyibogamine (noribogaine). Blood concentration-time effect profiles of ibogaine and noribogaine obtained for individual subjects after single oral dose administrations demonstrate complex pharmacokinetic profiles. Ibogaine has shown preliminary efficacy for opiate detoxification and for short-term stabilization of drug-dependent persons as they prepare to enter substance abuse treatment. We report here that ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification. Self-reports of depressive symptoms were also significantly lower after ibogaine treatment and at 30 days after program discharge. Because ibogaine is cleared rapidly from the blood, the beneficial aftereffects of the drug on craving and depressed mood may be related to the effects of noribogaine on the central nervous system.

AB - Ibogaine is an indole alkaloid found in the roots of Tabernanthe Iboga (Apocynaceae family), a rain forest shrub that is native to western Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and thirst, and in higher doses as a sacrament in religious rituals. Members of American and European addict self-help groups have claimed that ibogaine promotes long-term drug abstinence from addictive substances, including psychostimulants and opiates. Anecdotal reports attest that a single dose of ibogaine eliminates opiate withdrawal symptoms and reduces drug craving for extended periods of time. The purported efficacy of ibogaine for the treatment of drug dependence may be due in part to an active metabolite. The majority of ibogaine biotransformation proceeds via CYP2D6, including the O-demethylation of ibogaine to 12-hydroxyibogamine (noribogaine). Blood concentration-time effect profiles of ibogaine and noribogaine obtained for individual subjects after single oral dose administrations demonstrate complex pharmacokinetic profiles. Ibogaine has shown preliminary efficacy for opiate detoxification and for short-term stabilization of drug-dependent persons as they prepare to enter substance abuse treatment. We report here that ibogaine significantly decreased craving for cocaine and heroin during inpatient detoxification. Self-reports of depressive symptoms were also significantly lower after ibogaine treatment and at 30 days after program discharge. Because ibogaine is cleared rapidly from the blood, the beneficial aftereffects of the drug on craving and depressed mood may be related to the effects of noribogaine on the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=0033711410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033711410&partnerID=8YFLogxK

M3 - Article

VL - 914

SP - 394

EP - 401

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -